Acute leukemia of ambiguous lineage | UniteRare Disease Library

Overview

Also known as:

Acute leukemia of indeterminate lineage Hybrid acute leukemia Mixed lineage acute leukemia

FDA & Trial Timeline

10 events

Jun 2026Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms

Fred Hutchinson Cancer Center — NA

TrialNOT YET RECRUITING

Sep 2025Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Fred Hutchinson Cancer Center — PHASE2

TrialRECRUITING

Jun 2025Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

National Cancer Institute (NCI) — PHASE2

TrialRECRUITING

Jul 2024Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Fred Hutchinson Cancer Center — PHASE2

TrialRECRUITING

Jan 2024A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Children's Oncology Group — PHASE2

TrialACTIVE NOT RECRUITING

Jul 2023Venetoclax Combined With Azactidine in the Treatment of ALAL

Sheng-Li Xue, MD — PHASE2

TrialRECRUITING

May 2023MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Masonic Cancer Center, University of Minnesota — PHASE2

TrialRECRUITING

Feb 2022A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sumitomo Pharma America, Inc. — PHASE1, PHASE2

TrialRECRUITING

Nov 2021Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

St. Jude Children's Research Hospital — PHASE1

TrialACTIVE NOT RECRUITING

Apr 2021AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Mitchell Cairo — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Acute leukemia of ambiguous lineage.

12 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

12 recruitingView all trials with filters →

Phase 28 trials

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Phase 2

Actively Recruiting Prior treatment eligible

PI: Mitchell S Cairo (New York Medical College) · Sites: Valhalla, New York · Age: 1–30 yrs

Venetoclax Combined With Azactidine in the Treatment of ALAL

Phase 2

Actively Recruiting

· Sites: Suzhou · Age: 15–99 yrs

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Phase 2

Actively Recruiting

· Sites: Tianjin, Tianjin Municipality · Age: 14–99 yrs

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Phase 2

Actively Recruiting

PI: Filippo Milano, MD, PhD (Fred Hutch/University of Washington Cancer Consort) · Sites: Seattle, Washington · Age: 18–99 yrs

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Phase 2

Actively Recruiting

PI: Erin H Breese (Children's Oncology Group) · Sites: Birmingham, Alabama; Anchorage, Alaska +102 more

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Phase 2

Actively Recruiting

PI: Ann Dahlberg (Fred Hutch/University of Washington Cancer Consort) · Sites: Seattle, Washington · Age: 0–65 yrs

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Phase 2

Active

PI: Kelly E Faulk (Children's Oncology Group) · Sites: Birmingham, Alabama; Little Rock, Arkansas +82 more · Age: 0–6 yrs

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase 2

Actively Recruiting Prior treatment eligible

PI: Margaret MacMillan (University of Minnesota Masonic Cancer Center) · Sites: Minneapolis, Minnesota · Age: 0–60 yrs

Phase 12 trials

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 1

Active

PI: Seth Karol, MD (St. Jude Children's Research Hospital) · Sites: San Diego, California; Boston, Massachusetts +6 more · Age: 2–30 yrs

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Phase 1

Actively Recruiting

PI: John Perentesis, MD (Children's Hospital Medical Center, Cincinnati) · Sites: Cincinnati, Ohio · Age: 1–39 yrs

N/A2 trials

Familial Investigations of Childhood Cancer Predisposition

N/A

Actively Recruiting

PI: Kim E. Nichols, MD (St. Jude Children's Research Hospital) · Sites: Memphis, Tennessee

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

N/A

Actively Recruiting

PI: Timothy Olson, MD, PhD (Children's Hospital of Philadelphia) · Sites: Philadelphia, Pennsylvania · Age: 0–25 yrs

Specialists

Showing 25 of 49View all specialists →

Daniel A Arber

CHICAGO, IL

Specialist

1 Acute leukemia of ambiguous lineage publication

Directions Travel grants

Olga K Weinberg

DALLAS, TX

Specialist